Ganpisetti Ramesh, Giridharan Sanjay, Vaskuri G S Sainaga Jyothi, Narang Nikesh, Basim Pratap, Dokmeci Mehmet Remzi, Ermis Menekse, Rojekar Satish, Gholap Amol D, Kommineni Nagavendra
Terasaki Institute of Biomedical Sciences, 21100 Erwin St, Woodland Hills, Los Angeles, CA 91367-3712, USA.
Arizona State University, 1151 S. Forest AV Tempe, Tempe, AZ 85281, USA.
Biomolecules. 2025 May 31;15(6):802. doi: 10.3390/biom15060802.
Cancer is a highly detrimental and fatal illness that poses a significant threat to human well-being. The pattern of cancer treatment is continuously being optimized by the advancement of old treatment approaches and the invention of novel treatment modes. Nanotechnology-based approaches are emerging as powerful candidates in the development of these advanced methods for treating tumors. This article provides a concise overview of nanotechnology for cancer or cancer nanomedicine and its applications. In light of prevalent issues, such as inadequate precision in targeting initial chemotherapy drugs, susceptibility of nucleic acid drugs to degradation, gene delivery, and the occurrence of common immune-related adverse events during immunotherapy, we explore the potential integration of nanomedicine with these treatment approaches and illustrative examples and highlight the benefits that arise from the utilization of nanomedicine.
癌症是一种极具危害性和致命性的疾病,对人类健康构成重大威胁。随着传统治疗方法的进步和新型治疗模式的发明,癌症治疗模式在不断优化。基于纳米技术的方法正成为开发这些先进肿瘤治疗方法的有力候选者。本文简要概述了用于癌症治疗的纳米技术或癌症纳米医学及其应用。鉴于一些普遍存在的问题,如初始化疗药物靶向精准度不足、核酸药物易降解、基因递送以及免疫治疗期间常见免疫相关不良事件的发生等,我们探讨了纳米医学与这些治疗方法潜在的结合方式及实例,并强调了利用纳米医学所带来的益处。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024
Cochrane Database Syst Rev. 2018-2-6
Mol Biol Rep. 2025-6-21
Cochrane Database Syst Rev. 2021-11-16
Cochrane Database Syst Rev. 2025-6-19
Cochrane Database Syst Rev. 2018-7-12
Pharmaceuticals (Basel). 2025-7-3
Chem Bio Eng. 2024-1-9
J Control Release. 2025-3-10
Cancers (Basel). 2024-8-23
Nat Rev Mater. 2023-12
Int J Pharm. 2024-6-25
Front Oncol. 2024-4-10
J Colloid Interface Sci. 2024-8
Nat Rev Clin Oncol. 2024-6